摘要
目的:观察信迪利单抗联合TP化疗方案治疗中晚期食管癌患者的效果。方法:选取2020—2022年该院收治的100例中晚期食管癌患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各50例。对照组采用TP化疗方案治疗,研究组在对照组基础上联合信迪利单抗治疗,比较两组临床疗效,治疗前后肿瘤标志物[血管内皮生长因子(VEGF)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)]水平、生存质量[Karnofsky功能状态(KPS)]评分、1年存活率和不良反应发生率。结果:研究组客观缓解率(ORR)为84.21%(43/50),高于对照组的63.16%(31/50),差异有统计学意义(P<0.05);治疗后,两组VEGF、CEA、NSE水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);研究组KPS评分和1年存活率均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:信迪利单抗联合TP化疗方案治疗中晚期食管癌患者可提高ORR、KPS评分和1年存活率,降低肿瘤标志物水平,其效果优于单纯TP化疗方案治疗。
Objective:To observe effects of Sindilumab combined with TP chemotherapy in treatment of patients with advanced esophageal cancer.Methods:A prospective study was conducted on 100 patients with advanced esophageal cancer admitted to this hospital from 2020 to 2022.According to the random number table method,they were divided into study group and control group,50 cases in each group.The control group was treated with TP chemotherapy regimen,while the study group was treated with Sindilumab on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)]before and after the treatment,the quality of life[Karnofsky functional status(KPS)]score,the 1-year survival rate,and the incidence of adverse reactions were compared between the two groups.Results:The objective response rate(ORR)of the study group was 84.21%(43/50),which was higher than 63.16%(31/50)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of VEGF,CEA and NSE in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The KPS score and the 1-year survival rate of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sindilimab combined with TP chemotherapy in the treatment of the patients with advanced esophageal cancer can improve the ORR,the KPS scores and the 1-year survival rate,and reduce the levels of tumor markers.Moreover,it is superior to simple TP chemotherapy treatment.
作者
路璐
LU Lu(Department of Oncology of Xiuwu County People’s Hospital,Jiaozuo 454350 Henan,China)
出处
《中国民康医学》
2024年第18期48-50,共3页
Medical Journal of Chinese People’s Health
作者简介
路璐(1990.11-),女,汉族,河南焦作人,本科,主治医师,研究方向为肿瘤内科、肿瘤介入。
